

## LITERATURA

- de Koning HD. Schnitzler's syndrome: lessons from 281 cases. *Clin Transl Allergy* 2014; 4: 41–45.
- Mulla E, Neame R. Delayed development of the IgM paraprotein in Schnitzler's syndrome. *Scand J Rheumatol* 2015; 44: 521–522.
- Willekens I, Walgraeve N, Goethals L et al. Correlative bone imaging in a case of Schnitzler's syndrome and brief review of the literature. *Hell J Nucl Med* 2015; 18: 71–73.
- Hrodek O. Schnitzler syndrome: an under-diagnosed clinical entity *Transfuzie a hematologie dnes*. 2013; 19(4): 214–215.
- Janíková-Obořilová, Adam Z. Schnitzlerův syndrom *Vnitřní lék* 1998; 44 (7): 423–4274.
- Lipsker D, Veran Y, Grunenberger F et al. The Schnitzler syndrome. Four new cases and review of the literature. *Medicine (Baltimore)* 2001; 80: 37–44.
- Simon A, Asli B, Braun-Falco M et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. *Allergy* 2013; 68: 562–568.
- Kacar M, Pathak S, Savic S. Hereditary systemic autoinflammatory diseases and Schnitzler's syndrome *Rheumatology (Oxford)* 2019; 58(Suppl 6): 31–43.
- Basile C, Rossi L, Casucci F et al. Kidney involvement in the Schnitzler syndrome, a rare disease. *Clin Kidney J*. 2017; 10(6): 723–727. doi: 10.1093/ckj/sfx077.
- Jain T, Offord CP, Kyle RA, Dingli D. Schnitzler syndrome: an under-diagnosed clinical entity. *Haematologica*. 2013; 98(10): 1581–1585. doi: 10.3324/haematol.2013.084830.
- Terpos E, Asli B, Christoulas D, Brouet J-C, Kastiris E, Rybojad M et al. Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. *Haematologica*. 2012; 97(11): 1699–1703.
- Niederhauser BD, Dingli D, Kyle RA, Ringle MD. Imaging findings in 22 cases of Schnitzler syndrome: characteristic Para-articular osteosclerosis, and the "hot knees" sign differential diagnosis. *Skeletal Radiol*. 2014; 43(7): 905–915.
- Darrieurtort-Laffite C, Ansqer C, Aubert H et al. Rheumatic involvement and bone scan features in Schnitzler syndrome: initial and follow-up data from a single-center cohort of 25 patients. *Arthritis Res Ther*. 2020; 22(1): 272. doi: 10.1186/s13075-020-02318-5.
- Alix L, Néel A, Cador B et al. Diagnostic value of 18-F fluorodeoxyglucose PET/CT and bone scan in Schnitzler syndrome. *Autoimmunity*. 2019; 52(7–8): 264–271. doi: 10.1080/08916934.2019.1680649.
- Bursztejn AC, Imperiale A, Lipsker D. Aortitis: A new feature of Schnitzler syndrome. *JAAD Case Rep*. 2017; 3(5): 454–456. doi: 10.1016/j.jidcr.2017.06.016. PMID: 28971133; PMCID: PMC5602823.
- Kyle RA, Therneau TM, Rajkumar SV et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. *Blood*. 2003; 102(10): 3759–3764.
- Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. *Semin Oncol*. 2003; 30(2): 110–115.
- Elba S, Castellino A, Soriasio R et al. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. *J Med Case Rep*. 2020; 14(1): 75. doi: 10.1186/s13256-020-02380-2. PMID: 32564775; PMCID: PMC7310052.
- Gerz MA: Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. *Amer J Hematol*. 2021; 96(2): 258–269.
- Gavriatopoulou M, Musto P, Caers J et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Lukemia*. 2018 Sep; 32(9): 1883–1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. PMID: 30038381.
- Kastritis E, Leblond V, Dimopoulos MA, ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018; 29(Suppl 4): iv41–iv50. doi: 10.1093/annonc/mdy146.
- Aouba A, Pressiat C, Pricopi M et al. Complete remission of Schnitzler syndrome and Waldenström macroglobulinemia under rituximab-cyclophosphamide-dexamethasone. *Dermatology* 2015; 230(1): 18–22.
- Cascavilla N, Bisceglia M, D'Arena G. Successful treatment of Schnitzler's syndrome with anakinra after failure of rituximab trial. *Int J Immunopathol Pharmacol* 2010; 23(2): 633–636.
- Murota H, Shoda Y, Ishibashi T et al. Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy. *J Am Acad Dermatol* 2009; 61(6): 1070–1075.
- Eiling E, Möller M, Kreiselmaier I et al. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. *J Am Acad Dermatol* 2007; 57(2): 361–364.
- Ramadan KM, Eswedi HA, El-Agnaf MR. Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab. *Br J Dermatol* 2007; 156(5): 1072–1074.
- Husak R, Nestoris S, Goerdts S et al. Severe course of chronic urticaria, arthralgia, fever and elevation of erythrocyte sedimentation rate: Schnitzler's syndrome without monoclonal gammopathy? *Br J Dermatol* 2000; 142: 581–582.
- Cristina T, Varella N, Nishimura MY et al. Schnitzler's syndrome without monoclonal gammopathy. *Acta Derm Venereol* 2005; 85: 272–273.
- Jani P, Vissing MB, Ahmed S et al. Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition. *J Oncol Pract*. 2018; 14(6): 387–388. doi: 10.1200/JOP.18.00050. Epub 2018 Mar 20.
- Doležalová P. Nové indikace léčby anakinrou *Farmakoterapie (Praha, Print)* 2019; 15(3): 333–337.
- Šedivá, A, Sliva J, Doležalová P et al. Anakinra *Farmakoterapie (Praha, Print)* 2011; 7(6): 621–629.
- Néel A, Henry B, Barbarot S et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A French multicenter study. *Autoimmun Rev* 2014; 13: 1035–1041.
- Rowczenio DM, Pathak S, Arostegui JI et al. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. *Blood*. 2018; 131(9): 974–981. doi:10.1182/blood-2017-10-810366.
- Vanderschueren S, van der Veen A. The Schnitzler syndrome: chronic urticaria in disguise: a single-centre report of 11 cases and a critical reappraisal of the literature. *Clin Exp Rheumatol*. 2017; 35(1): 69–73.
- Giurgea I, Grateau G, Georgin-Lavialle S; French Network of Dysimmune Disorders Associated with Hemopathies. Monoclonal Gammopathy, Arthralgias, and Recurrent Fever Syndrome: A New Autoinflammatory Syndrome? *J Rheumatol*. 2019; 46(11): 1535–1539. doi: 10.3899/jrheum.181204.
- Soudet S, Fajgenbaum D, Delattre C et al. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. *Curr Res Transl Med*. 2018; 66(3): 83–86. doi: 10.1016/j.retram.2018.06.001.
- Gorodetskiy VR, Salugina SO, Fedorov ES. Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome. *Case Rep Rheumatol*. 2018; 2018:5416907. doi: 10.1155/2018/5416907. PMID: 29850358; PMCID: PMC5925130.
- Fujita Y, Asano T, Sakai A et al. A case of Schnitzler's syndrome without monoclonal gammopathy successfully treated with canakinumab. *BMC Musculoskelet Disord*. 2021; 22(1): 257. doi: 10.1186/s12891-021-04120-z. Betraíns A, Staelis F, Vanderschueren S. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review. *Semin Arthritis Rheum*. 2020; 50(4): 636–642. doi: 10.1016/j.semarthrit.2020.05.002.
- Krause K, Tsianakas A, Wagner N et al. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. *J Allergy Clin Immunol*. 2017; 139(4): 1311–1320.
- Krause K, Bonnekoh H, Ellrich A et al. Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome. *J Allergy Clin Immunol*. 2020; 145(6): 1681–1686.e5. doi:10.1016/j.jaci.2019.12.909.
- Betraíns A, Staelis F, Vanderschueren S. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review. *Semin Arthritis Rheum*. 2020; 50(4): 636–642. doi: 10.1016/j.semarthrit.2020.05.002.
- Krause K, Feist E, Fiene M et al. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. *J Allergy Clin Immunol* 2012; 129: 848–850.
- Claus J, Vanderschueren S. Variable Responses to Tocilizumab in Four Patients with Schnitzler Syndrome. *J Clin Immunol* 2019; 39(4): 370–372.
- Yan R, Cao W, Liu X, Li F, Shen M. A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-treated patient. *Clin Rheumatol*. 2020; 39(12): 3847–3852.
- Kluger N, Bessis D, Guillot B. Tocilizumab as a potential treatment in Schnitzler syndrome. *Med Hypotheses* 2009; 72(4): 479–480.
- Więsik-Szewczyk E, Felis-Giemza A et al. Schnitzler Syndrome in a 27-Year-Old Man: Diagnostic and Therapeutic Dilemma in Adult Auto-Inflammatory Syndromes A Case Report and Literature Review. *Int J Gen Med*. 2020; 13: 713–719. doi: 10.2147/IJGM.S265482
- Bonnekoh H, Frischbutter S, Roll S et al. Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study. *J Allergy Clin Immunol Pract*. 2021; S2213–2198(21)00152-5. doi: 10.1016/j.jaip.2021.01.024.
- Castillo JJ, Advani RH, Branagan AR et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. *Lancet Haematol*. 2020; 7(11): e827–e837. doi:10.1016/S2352-3026(20)30224-6.
- Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. *Br J Haematol*. 2016; 175(1): 77–86. doi: 10.1111/bjh.14196.